Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Feb 1, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NCI CTEP-Approved Trials for the Month of January

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase III

S1400I: A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study). SWOG; Papadimitrakopoulou, Vassiliki A. (713) 792-6363

 

Other Phases

AAML15B6-Q: Use of DNA Methylation Assessment by xMELP for Prognosis in Pediatric Patients with Acute Myeloid Leukemia. Children’s Oncology Group Wertheim, Gerald. (267) 970-5918

 

ANBL14B4-Q: Correlation Between Tumor Stage and MXI1 & MXI0 Expression in Neuroblastoma Tumor Samples. Children’s Oncology Group; Armstrong, Michael Brannon. (919) 684-3401

 

ANBL14B6-Q: Development of a miRNA Serum Signature for Minimally Invasive and Accurate Outcome Prediction of High-Risk Neuroblastoma Patients. Children’s Oncology Group; Vandesompele, Jo. 32 9 332 5187

 

ARST15B1-Q: Genetic Susceptibility in Rhabdomyosarcoma. Children’s Oncology Group; Lupo, Philip. (713) 798-2960



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter